We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
-0.26%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$370M
AUM Growth
+$3.92M
Cap. Flow
+$17.1M
Cap. Flow %
4.63%
Top 10 Hldgs %
94.7%
Holding
17
New
2
Increased
2
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
CMPI
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
+$17.1M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$11.7M
3
IMUX icon
Immunic
IMUX
+$6.82M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$59K

Top Sells

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$8.48M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$4.96M
3
EPIX
ESSA Pharma
EPIX
+$3.97M
4
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$1.21M
5
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$11.5K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
1
Replimune Group
REPL
$814M
$122M 33.11%
5,344,971
– –
MORF
2
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$81.4M 22.02%
2,977,832
+2,250
+0.1% +$59K
GOSS icon
3
Gossamer Bio
GOSS
$66.5M
$41.2M 11.15%
3,320,608
– –
IMUX icon
4
Immunic
IMUX
$182M
$33.2M 8.98%
178,816
+41,667
+30% +$6.82M
ARQT icon
5
Arcutis Biotherapeutics
ARQT
$3.42B
$19.3M 5.22%
658,908
-185,772
-22% -$4.96M
CMPI
6
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$15.4M 4.16%
+1,335,050
New +$17.1M
PRTK
7
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$14.1M 3.81%
2,600,410
-2,329
-0.1% -$11.5K
ALPN
8
DELISTED
Alpine Immune Sciences Inc
ALPN
$11.3M 3.06%
+1,284,900
New +$11.7M
EPIX
9
DELISTED
ESSA Pharma
EPIX
$6.1M 1.65%
912,693
-584,755
-39% -$3.97M
CDTX
10
DELISTED
Cidara Therapeutics
CDTX
$5.71M 1.55%
100,262
– –
TRVI icon
11
Trevi Therapeutics
TRVI
$2.49B
$5.54M 1.5%
1,375,907
– –
KYNB
12
Kyntra Bio
KYNB
$28.5M
$5.37M 1.45%
5,226
– –
JNCE
13
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.73M 0.74%
334,965
-195,000
-37% -$1.21M
OBSV
14
DELISTED
ObsEva SA Ordinary Shares
OBSV
$2.48M 0.67%
999,364
– –
PRVL
15
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$1.91M 0.52%
187,538
– –
PVLA
16
Palvella Therapeutics
PVLA
$1.98B
$1.55M 0.42%
9,384
– –
BEAM icon
17
Beam Therapeutics
BEAM
$2.58B
– –
-302,821
Closed -$8.48M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q3 2020 Portfolio in Review

As of Q3 2020, Omega Fund Management held 17 positions worth $370M, up 1.1% from $366M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Omega Fund Management deployed $17.1M of net new capital in Q3 2020, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Checkmate Pharmaceuticals, Inc. Common Stock: 1,335,050 shares worth $15.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Arcutis Biotherapeutics, an estimated $4.96M trimmed.

  • Omega Fund Management's largest Q3 2020 buy was Checkmate Pharmaceuticals, Inc. Common Stock: 1,335,050 shares worth $15.4M.
  • Omega Fund Management added most to Immunic in Q3 2020, an estimated $6.82M increase.
  • Omega Fund Management's biggest Q3 2020 reduction was Arcutis Biotherapeutics, cutting an estimated $4.96M.
  • Omega Fund Management fully exited Beam Therapeutics in Q3 2020, selling an estimated $8.48M.
  • Omega Fund Management's ten largest holdings make up 95% of its $370M portfolio in Q3 2020.
  • Omega Fund Management opened 2 new positions and closed 1 in Q3 2020.
  • Omega Fund Management's portfolio value rose 1.1% quarter-over-quarter to $370M.

Based on Omega Fund Management's 13F filing for Q3 2020, filed 16 Nov 2020.